A metabolic syndrome independent association between overweight, fibrinolysis impairment and low-grade inflammation in young women with venous thromboembolism

Blood Coagulation and Fibrinolysis

Volumn 17, Issue 7, 2006, Pages 551-556

  Salobir, Barbara ^a   Sabovic, Miso ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Fibrinolysis; Inflammation; Overweight; Sedimentation rate; Venous thromboembolism; Young women

Indexed keywords

BLOOD GROUP ANTIGEN; D DIMER; FIBRINOGEN; INSULIN; INTERLEUKIN 6; LIPID; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 1 ANTIGEN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; INFLAMMATION; METABOLIC SYNDROME X; OBESITY; PREDICTION; PRIORITY JOURNAL; RISK; SEDIMENTATION RATE; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADULT; BLOOD SEDIMENTATION; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYSIS; HUMANS; INFLAMMATION; METABOLIC SYNDROME X; MIDDLE AGED; OVERWEIGHT; RISK FACTORS; VENOUS THROMBOSIS;

EID: 33748919110     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000245298.64644.0a     Document Type: Article

References (18)

1. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995: 346:1575-1582.
2. Nightingale AL, Lawrenson RA, Simpson EL, Williams TJ, MacRae KD, Farmer RD. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000; 5:265-274.
3. Farmer RD, Lawrenson RA, Todd JC, Williams TJ, MacRae KD, Tyrer F, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Pharmacol 2000; 49:580-590.
4. Vague P, Juhan-Vague I, Chabert V, Alessi MC, Atlan C. Fat distribution and plasminogen activator inhibitor activity in non diabetic obese women. Metabolism 1989; 38:913-915.
5. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46:860-867.
6. Mavri A, Stegnar M, Krebs M, Sentocnik JT, Geiger M, Binder BR. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler Thromb Vasc Biol 1999; 6:1582-1587.
7. Koenig W. Haemostatic risk factors for cardiovascular diseases. Eur Heart J 1998; 19:C39-C43.
8. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1:1575-1579.
9. Mavri A, Alessi MC, Juhan-Vague I. Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases. J Intern Med 2004; 255:448-456.
10. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. A multinational case-control study of cardiovascular disease and steroid hormone contraceptives: description and validation of methods. J Clin Epdiemiol 1995; 48:1513-1547.
11. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90:1004-1008.
12. Buckell M. The effect of citrate on euglobulin methods of estimating fibrinolytic activity. J Clin Pathol 1958; 11:403-405.
13. Bastelica D, Mavri A, Verdier M, Berthet B, Juhan-Vague I, Alessi MC. Relationship between fibrinolytic and inflammatory parameters in human adipose tissue: strong contribution of TNFα receptors to PAI-1 levels. Thromb Haemost 2002; 88:481-487.
14. Yudkin JS, Juhan-Vague I, Hawe E, Humphries SE, di Minno G, Margaglione M, et al., on behalf of the HIFMECH study group. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 2004; 53:852-857.
15. Lemieux I, Pascot A, Prud'homme D, Almeras N, Bogaty P, Nadeau A, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001; 21:881-883.
16. Samocha-Bonet D, Lichtenberg D, Tomer A, Deutsch V, Mardi T, Goldin Y, et al. Enhanced erythrocyte adhesiveness/aggregation in obesity corresponds to low-grade inflammation. Obes Res 2003; 11:403-407.
17. Ami RB, Barshtein G, Zeltser D, Goldberg Y, Shapira I, Roth A, et al. Parameters of red blood cell aggregation as correlate of the inflammatory state. Am J Physiol Heart Circ Physiol 2001; 280:H1982-H1988.
18. Soutani M, Suzuki Y, Tateishi N, Maeda N. Quantitative evaluation of flow dynamics of erythrocytes in microvessels: influence of erythrocyte aggregation. Am J Physiol 1995; 268:H1959-H1965.